134 related articles for article (PubMed ID: 24121041)
1. Circulating IL-35 in pancreatic ductal adenocarcinoma patients.
Jin P; Ren H; Sun W; Xin W; Zhang H; Hao J
Hum Immunol; 2014 Jan; 75(1):29-33. PubMed ID: 24121041
[TBL] [Abstract][Full Text] [Related]
2. Decreased IL-35 levels in patients with immune thrombocytopenia.
Yang Y; Xuan M; Zhang X; Zhang D; Fu R; Zhou F; Ma L; Li H; Xue F; Zhang L; Yang R
Hum Immunol; 2014 Aug; 75(8):909-13. PubMed ID: 24994465
[TBL] [Abstract][Full Text] [Related]
3. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
4. [Expression and clinical significance of Tspan 1 and Integrin α6 in human pancreatic ductal adenocarcinoma].
Shi G; Dong M; Sheng W; Zhou J; Yu D; Sun W
Zhonghua Wai Ke Za Zhi; 2014 Oct; 52(10):781-6. PubMed ID: 25573220
[TBL] [Abstract][Full Text] [Related]
5. High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.
Wen Z; Liao Q; Zhao J; Hu Y; You L; Lu Z; Jia C; Wei Y; Zhao Y
Ann Surg Oncol; 2014 Jan; 21(1):125-32. PubMed ID: 24132627
[TBL] [Abstract][Full Text] [Related]
6. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer.
Abue M; Yokoyama M; Shibuya R; Tamai K; Yamaguchi K; Sato I; Tanaka N; Hamada S; Shimosegawa T; Sugamura K; Satoh K
Int J Oncol; 2015 Feb; 46(2):539-47. PubMed ID: 25384963
[TBL] [Abstract][Full Text] [Related]
7. An exploratory study of inflammatory cytokines as prognostic biomarkers in patients with ductal pancreatic adenocarcinoma.
Dima SO; Tanase C; Albulescu R; Herlea V; Chivu-Economescu M; Purnichescu-Purtan R; Dumitrascu T; Duda DG; Popescu I
Pancreas; 2012 Oct; 41(7):1001-7. PubMed ID: 22722257
[TBL] [Abstract][Full Text] [Related]
8. Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer.
Niccolai E; Taddei A; Ricci F; Rolla S; D'Elios MM; Benagiano M; Bechi P; Bencini L; Ringressi MN; Pini A; Castiglione F; Giordano D; Satolli MA; Coratti A; Cianchi F; Bani D; Prisco D; Novelli F; Amedei A
Clin Sci (Lond); 2016 Feb; 130(4):247-58. PubMed ID: 26590104
[TBL] [Abstract][Full Text] [Related]
9. Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation.
Arnoletti JP; Zhu X; Almodovar AJ; Veldhuis PP; Sause R; Griffith E; Corpus G; Chang JC; Fanaian N; Litherland SA
Pancreas; 2017 Jan; 46(1):116-123. PubMed ID: 27400259
[TBL] [Abstract][Full Text] [Related]
10. Lower Plasma Levels of IL-35 in Patients with Primary Biliary Cirrhosis.
Li T; Huang Y; Liu P; Liu Y; Guo J; Zhang W; Gu M; Qian C; Deng A
Tohoku J Exp Med; 2018 Feb; 244(2):123-131. PubMed ID: 29445068
[TBL] [Abstract][Full Text] [Related]
11. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications and diagnostic usefulness of correlation between soluble major histocompatibility complex class I chain-related molecule a and protumorigenic cytokines in pancreatic ductal adenocarcinoma.
Chung HW; Jang S; Lim JB
Cancer; 2013 Jan; 119(1):233-44. PubMed ID: 22736451
[TBL] [Abstract][Full Text] [Related]
13. Levels of Alternatively Spliced Tissue Factor in the Plasma of Patients with Pancreatic Cancer May Help Predict Aggressive Tumor Phenotype.
Unruh D; Sagin F; Adam M; Van Dreden P; Woodhams BJ; Hart K; Lindsell CJ; Ahmad SA; Bogdanov VY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1206-11. PubMed ID: 25963480
[TBL] [Abstract][Full Text] [Related]
14. [Expression of IL-35, Epstein-Barr virus-induced gene 3 mRNA and IL-12A mRNA in peripheral blood of patients with allergic rhinitis].
Wan J; Luo Y; Yang C; Liu J; Du Y; Wang K
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Jul; 28(13):952-4. PubMed ID: 25248258
[TBL] [Abstract][Full Text] [Related]
15. Improving the accuracy of pancreatic cancer clinical staging by exploitation of nanoparticle-blood interactions: A pilot study.
Caputo D; Cartillone M; Cascone C; Pozzi D; Digiacomo L; Palchetti S; Caracciolo G; Coppola R
Pancreatology; 2018 Sep; 18(6):661-665. PubMed ID: 29914752
[TBL] [Abstract][Full Text] [Related]
16. Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma.
Dambrauskas Z; Svensson H; Joshi M; Hyltander A; Naredi P; Iresjö BM
Int J Oncol; 2014 Jan; 44(1):99-104. PubMed ID: 24173243
[TBL] [Abstract][Full Text] [Related]
17. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
[TBL] [Abstract][Full Text] [Related]
18. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.
Zhang J; Zhao CY; Zhang SH; Yu DH; Chen Y; Liu QH; Shi M; Ni CR; Zhu MH
Oncol Rep; 2014 Mar; 31(3):1157-64. PubMed ID: 24398877
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report.
Yako YY; Brand M; Smith M; Kruger D
Pancreatology; 2017; 17(3):438-444. PubMed ID: 28377069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
